Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanylin is an endogenous peptide hormone that acts as a ligand for the receptor guanylate cyclase C (GC-C), primarily expressed on the apical membrane of intestinal mucosal cells. Its activation of GC-C leads to the production of intracellular cyclic guanosine monophosphate (cGMP), which subsequently activates protein kinase G II (PKGII) and the cystic fibrosis transmembrane conductance regulator (CFTR). This signaling pathway is crucial for regulating intestinal fluid and electrolyte balance, maintaining intestinal pH, and preventing hypernatremia. Guanylin also plays a role in maintaining the hydrated state of colonic mucus, influencing commensal microorganisms and bowel clearance. Dysregulation of the GC-C/cGMP signaling axis, including loss of guanylin expression, is implicated in various conditions such as functional gastrointestinal disorders, inflammatory bowel disease, visceral pain, and colorectal cancer, making the GC-C pathway a promising therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanylin.